Published in Blood Weekly, March 3rd, 2005
All of the over-allotment shares were sold by the company. After giving effect to the sale of the over-allotment shares, a total of 18,400,000 common shares were offered and sold by the company in the initial public offering for gross proceeds to the company of CDN$18,400,000.
A syndicate of investment dealers led by Canaccord Capital Corp. and including Jennings Capital, Inc., McFarlane...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.